Autor(es):
Kissling, Esther ; Valenciano, Marta ; Pozo, Francisco ; Vilcu, Ana-Maria ; Reuss, Annicka ; Rizzo, Caterina ; Larrauri, Amparo ; Horváth, Judit Krisztina ; Brytting, Mia ; Domegan, Lisa ; Korczyńska, Monika ; Meijer, Adam ; Machado, Ausenda ; Ivanciuc, Alina ; Višekruna Vučina, Vesna ; van der Werf, Sylvie ; Schweiger, Brunhilde ; Bella, Antonino ; Gherasim, Alin ; Ferenczi, Annamária ; Zakikhany, Katherina ; O Donnell, Joan ; Paradowska-Stankiewicz, Iwona ; Dijkstra, Frederika ; Guiomar, Raquel ; Lazar, Mihaela ; Kurečić Filipović, Sanja ; Johansen, Kari ; Moren, Alain ; I-MOVE/I-MOVE+ study team
Data: 2018
Identificador Persistente: http://hdl.handle.net/10400.18/5062
Origem: Repositório Científico do Instituto Nacional de Saúde
Assunto(s): Case Control Study; Influenza; influenza Vaccine; Multicentre Study; Vaccine Effectiveness; Cuidados de Saúde; Efetividade da Vacina Antigripal; Vacina Antigripal; I-MOVE; I-MOVE+
Descrição
Background:During the 2015/16 influenza season in Europe, the co-circulating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. Methods:We used the test negative design in a multicentre case–control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients ainfluenza Vaccinend a random sample of influenza positive swabs were sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. Results: We included 11,430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0–14, 15–64 and ≥65 years VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3-65.0), 41.4% (95%CI: 20.5-56.7) and 13.2% (95% CI: -38.0-45.3) respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95%CI: -4.1-56.7). Among those aged 0–14, 15–64 and ≥65 years VE against influenza B was -47.6% (95%CI: -124.9-3.1), 27.3% (95%CI: -4.6-49.4), and 9.3% (95%CI: -44.1-42.9) respectively. Conclusions: VE against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. VE against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection are needed to understand the VE results against influenza B in the context of a mismatched vaccine.
